<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031274</url>
  </required_header>
  <id_info>
    <org_study_id>19-178923</org_study_id>
    <nct_id>NCT04031274</nct_id>
  </id_info>
  <brief_title>Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry</brief_title>
  <acronym>AMTRAC</acronym>
  <official_title>International Multicenter Registry of Patients With Concomitant Aortic and Mitral Valve Disease Undergoing Transcatheter Aortic Valve Implantation - The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinique Pasteur</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Catania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Institute Saint Ambrogio, Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Galway University Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teikyo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniche Humanitas Gavazzeni</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>G. Pasquinucci Heart Hospital, Massa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Victoria Hospital , Belfast</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiovascular Center Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      an international multicentre registry designed to answer 3 clinical questions:&#xD;
&#xD;
        1. Describing the characteristics and outcomes of current patients undergoing aortic +&#xD;
           mitral transcatheter heart valve procedures.&#xD;
&#xD;
        2. Better understanding of the predictors for MR regression following isolated TAVI and&#xD;
           consequently estimating the fraction of patients who will be suitable for TMVR/r post&#xD;
           TAVI&#xD;
&#xD;
        3. Examining the clinical outcomes of patients with significant MR post TAVI who&#xD;
           subsequently underwent TMVR/r compared to those left for medical management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) , has revolutionised the treatment for severe&#xD;
      aortic stenosis (AS) over the past decade. The use of TAVI is growing exponentially, and the&#xD;
      current trend of treating younger and lower risk patients is expected to continue [1], with&#xD;
      TAVI eventually becoming the treatment of choice for the majority of severe AS patients. When&#xD;
      treating younger, lower risk patients, whose life expectancy is longer than that of current&#xD;
      typical TAVI patients, long term prognosis with good functional status is as significant as&#xD;
      periprocedural morbidity when selecting the preferred treatment strategy. Consequently,&#xD;
      treatment of comorbidities, especially cardiac comorbidities is of paramount importance.&#xD;
&#xD;
      Significant mitral regurgitation (MR) is present in approximately 25% of patients with severe&#xD;
      AS [2], there are several pathophysiological mechanisms linking the two entities [3,4].&#xD;
      Significant MR is associated with worse prognosis in patients undergoing either surgical&#xD;
      aortic valve replacement (SAVR) [5] or TAVI [6,7] . Using a surgical intervention, both AS&#xD;
      and MR can be treated (albeit at a cost of increased perioperative mortality) [8], while&#xD;
      treating both valves using a transcatheter technique in a single procedure is not customary.&#xD;
      A sizeable fraction of patients from AS+MR will have some reduction in MR following TAVI [2],&#xD;
      but unlike the case of surgical double valve replacement [6], the prognostic benefit of MR&#xD;
      reduction following TAVI has not yet been shown [9].This issue may be of utmost importance in&#xD;
      patients who are viable surgical candidates, in whom the feasibility of total surgical&#xD;
      valvular treatment may be a &quot;tiebreaker&quot; when contemplating the pros and cons of&#xD;
      transcatheter vs. surgical intervention.&#xD;
&#xD;
      The percutaneous treatment options for MR with either transcatheter mitral valve replacement&#xD;
      (TMVR) or repair (TMVr) are expanding and clinical experience is growing [1], raising the&#xD;
      option for a combined percutaneous treatment for patients with AS+MR - either a combined TAVI&#xD;
      + TMVR/r procedure, or performing TAVI first followed by a TMVR/r for those patients whose MR&#xD;
      does not improve sufficiently following an isolated TAVI. One multicentre study from Spain&#xD;
      dedicated to patients with significant MR undergoing TAVI found two predictors for&#xD;
      persistence of MR following TAVI (mitral annular diameter of &gt;35.5 mm and the degree of&#xD;
      calcification of the mitral apparatus by multidetector computed tomography), and also&#xD;
      suggested that only a small fraction of such patients will be suitable for TMVR/r, but this&#xD;
      was based on a small number of patients (n=177) [10].&#xD;
&#xD;
      To examine whether such approach is appropriate, several evidence gaps will need to be&#xD;
      addressed:&#xD;
&#xD;
        1. describing the characteristics and outcomes of current patients undergoing aortic +&#xD;
           mitral transcatheter heart valve procedures.&#xD;
&#xD;
        2. Better understanding of the predictors for MR regression following isolated TAVI and&#xD;
           consequently estimating the fraction of patients who will be suitable for TMVR/r post&#xD;
           TAVI&#xD;
&#xD;
        3. Examining the clinical outcomes of patients with significant MR post TAVI who&#xD;
           subsequently underwent TMVR/r compared to those left for medical management.&#xD;
&#xD;
      To try and address these questions we propose to compile an international multicentre&#xD;
      registry focusing on patients with significant MR undergoing TAVI - the AMTRAC registry.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      A multicentre registry of interventional cardiology centres experienced in transcatheter&#xD;
      valvular interventions. This registry will be established in 2 phases (each centre will&#xD;
      choose whether it wishes to participate in both phases or just the initial phase):&#xD;
&#xD;
      Phase 1:&#xD;
&#xD;
      Collecting data on patients who underwent TAVI+TMVR/r (either as a single or staged&#xD;
      procedure).&#xD;
&#xD;
      This phase will focus on assessing the feasibility and safety of performing TAVI+TMVR/r&#xD;
      procedures and will adress 2 clinical question:&#xD;
&#xD;
        1. Describing the demographic, clinical and imaging characteristics of patients undergoing&#xD;
           TAVI+TMVR/r in current clinical practice&#xD;
&#xD;
        2. Describing the clinical outcomes (with focus on 30 day outcomes) of patients undergoing&#xD;
           TAVI+TMVR/r in current clinical practice&#xD;
&#xD;
      Phase 2:&#xD;
&#xD;
      Adding data on the overall TAVI population of the participating centres.&#xD;
&#xD;
      This phase will be directed at assessing the prevalence, clinical significance, and optimal&#xD;
      treatment strategies of TAVI patients who also suffer from significant MR and will address 5&#xD;
      clinical questions:&#xD;
&#xD;
        1. The prevalence of significant MR in patients undergoing TAVI&#xD;
&#xD;
        2. The effect of isolated TAVI on MR in these patients&#xD;
&#xD;
        3. The prognostic effect of significant MR persistence following isolated TAVI&#xD;
&#xD;
        4. The characteristics of patients with persistence of significant MR following isolated&#xD;
           TAVI (regarding pre-TAVI predictors of MR persistence and post TAVI suitability for&#xD;
           TMVR/r)&#xD;
&#xD;
        5. The outcomes of patients undergoing TMVR/r following isolated TAVI&#xD;
&#xD;
      Patient population&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      For phase 1:&#xD;
&#xD;
      TAVI+TMVR/r (either as a single or staged procedure). Follow up of at least 30 days post&#xD;
      TMVR/r (unless deceased) Available TTE and/or TOE data pre and post TAVI + TMVR/r&#xD;
&#xD;
      For phase 2:&#xD;
&#xD;
      Patients undergoing successful isolated TAVI Assessment of MR grade prior and post TAVI&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
      Death within 30 days post TAVI&#xD;
&#xD;
      Patient's data will be collected through the TAVI registries of each participating centre and&#xD;
      after anonymization of patient personal details will be sent to the coordinating centre&#xD;
      (Rabin Medical Centre) using a streamlined uniform CRF sheet that will be circulated to the&#xD;
      participating centres, this will include basic clinical, demographic, echocardiographic and&#xD;
      procedural data as well as post procedural clinical outcomes and echocardiographic&#xD;
      assessment.&#xD;
&#xD;
      For patients who have subsequently undergone TMVR/r - data on the availability of&#xD;
      pre-procedural imaging assessment (TOE, MDCT) and follow up TTE data will be collected as&#xD;
      well. When possible (according to the decision of each centre), we would request for the&#xD;
      imaging files for patients with significant MR post isolated TAVI to be sent to the&#xD;
      coordinating centre to be assessed by an imaging CoreLab&#xD;
&#xD;
      Study endpoints&#xD;
&#xD;
      Phase 1:&#xD;
&#xD;
      30 day mortality (from the date of TMVR/r) Periprocedural outcomes (according to the VARC II&#xD;
      criteria) NYHA class 30 days post TMVR/r Grade of MR 30 days post TMVR/r&#xD;
&#xD;
      Phase 2:&#xD;
&#xD;
      For all patients:&#xD;
&#xD;
      Grade of MR prior and following isolated TAVI (at least 30 days post TAVI) Periprocedural&#xD;
      outcomes (according to the VARC II criteria) Overall mortality at 1,6,12 months and longest&#xD;
      available follow up post TAVI NYHA class at 1,6,12, months and longest available follow up&#xD;
      (when available)&#xD;
&#xD;
      For patients with significant MR pre-TAVI:&#xD;
&#xD;
      Regression of MR grade post isolated TAVI Suitability for TMVR/r&#xD;
&#xD;
      For patients undergoing TMVR/r:&#xD;
&#xD;
      Grade of MR following TMVR/r&#xD;
&#xD;
      Definitions&#xD;
&#xD;
      Significant MR:&#xD;
&#xD;
      MR grade 3/4 (moderate+) as defined by each participating centre&#xD;
&#xD;
      TMVR/r:&#xD;
&#xD;
      Transcatheter procedure for the treatment of MR using any available percutaneous device.&#xD;
&#xD;
      Statistical methods&#xD;
&#xD;
      Phase 1:&#xD;
&#xD;
      Summary statistics of the baseline characteristics using mean +/- SD / median + IQR as&#xD;
      appropriate for continuous variables and counts (%) for categorical variables.&#xD;
&#xD;
      Graphic display of the cumulative risk for 30 day mortality using Kaplan-Meier curves Graphic&#xD;
      display of change in MR grade from baseline to 30 day using bar charts (using the Chi-square&#xD;
      test to determine statistical significance).&#xD;
&#xD;
      Identifying factors associated with 30 day mortality and 30 day persistence of MR using a&#xD;
      multivariate adjusted logistic regression model.&#xD;
&#xD;
      Phase 2:&#xD;
&#xD;
      Baseline characteristics will be compared between patients with/without significant MR prior&#xD;
      to TAVI. categorical variables will be reported as counts or percentages, continuous data as&#xD;
      means ±SD or median (interquartile range) as appropriate and compared using t-test or the&#xD;
      Wilcoxon sum rank test for continuous variables and Chi Square test for categorical variables&#xD;
      as appropriate. The probabilities 1 year and long term mortality according to MR category&#xD;
      will be plotted by Kaplan-Meier curves, with comparison of cumulative events by the log-rank&#xD;
      test. A multivariate adjusted cox regression model will be fitted to examine the association&#xD;
      of post TAVI mortality with baseline MR category.&#xD;
&#xD;
      The same analysis, restricted to patients with significant MR at baseline will be repeated to&#xD;
      compare the characteristics and post TAVI mortality between those with significant MR at&#xD;
      baseline whose MR has/has not post isolated TAVI.&#xD;
&#xD;
      To identify independent predictors of MR persistence post TAVI we shall fit a multivariate&#xD;
      logistic regression model with MR persistence as the outcome variable and all relevant&#xD;
      baseline clinical and imaging characteristics as covariates.&#xD;
&#xD;
      For all patients who remained with significant MR post TAVI, suitability for TMVR/r will be&#xD;
      assessed after CoreLab review of all available imaging data (TTE/TOE/MDCT).&#xD;
&#xD;
      Baseline characteristics of patients with significant MR post TAVI will be compared between&#xD;
      those suitable/unsuitable for TMVR/r as described above.&#xD;
&#xD;
      The preprocedural outcomes (in hospital complications and 30 day mortality) will be presented&#xD;
      for those patients undergoing TMVR/r.&#xD;
&#xD;
      Finally, the long term survival (starting from the date of TAVI) will be compared between 5&#xD;
      groups of patients stratified according to their baseline MR, it's response to TAVI and their&#xD;
      subsequent treatment strategy (see Figure 1):&#xD;
&#xD;
        1. No significant MR at baseline&#xD;
&#xD;
        2. Significant MR at baseline with regression post isolated TAVR&#xD;
&#xD;
        3. Persistence of significant MR post TAVI, unsuitable for TMVR/r&#xD;
&#xD;
        4. Persistence of significant MR post TAVI, suitable for TMVR/r, treated medically&#xD;
&#xD;
        5. Persistence of significant MR post TAVI, suitable for TMVR/r, treated with TMVR/r&#xD;
&#xD;
      Sample size For phase 1, our goal is to collect data on 50-100 patients who underwent TAVI +&#xD;
      TMVR/r (either as a single or staged procedure).&#xD;
&#xD;
      Based on the data by Cortes et al [10], assuming a baseline prevalence of 20% for severe MR,&#xD;
      with 40% persistence post TAVI and 13% of those cases suitable for TMVR/r - we would need a&#xD;
      sample size of just under 10,000 TAVI cases. We aim to include at least 15-20 high volume&#xD;
      TAVI centres in this registry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>UP to 10 years of follow up</time_frame>
    <description>Death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Periprocedural complications</measure>
    <time_frame>In-hospital/30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periprocedural mortality</measure>
    <time_frame>In-hospital/30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Class</measure>
    <time_frame>1,3,6,12 months and up to 10 years of follow up</time_frame>
    <description>Functional class according to the New York Heart Association scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation grade</measure>
    <time_frame>1,3,6,12 months and up to 10 years of follow up</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>TAVI no MR</arm_group_label>
    <description>Patients undergoing TAVI with MR up to moderate following the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVI + MR no further intervention</arm_group_label>
    <description>Patients undergoing TAVI with MR more than moderate following the procedure, no further mitral valve intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVI + MR undergoing TMVR/r</arm_group_label>
    <description>Patients undergoing TAVI with MR more than moderate following the procedure, underwent transcatheter mitral valve intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI</intervention_name>
    <description>Trascatheter aortic valve implantation</description>
    <arm_group_label>TAVI + MR no further intervention</arm_group_label>
    <arm_group_label>TAVI + MR undergoing TMVR/r</arm_group_label>
    <arm_group_label>TAVI no MR</arm_group_label>
    <other_name>TAVR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMVR/r</intervention_name>
    <description>Transcatheter mitral valve replacement/repair</description>
    <arm_group_label>TAVI + MR undergoing TMVR/r</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing TAVI who also have data regarding MR grade pre TAVI and at least 30&#xD;
        days post TAVI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For phase 1:&#xD;
&#xD;
          -  TAVI+TMVR/r (either as a single or staged procedure).&#xD;
&#xD;
          -  Follow up of at least 30 days post TMVR/r (unless deceased) Available TTE and/or TOE&#xD;
             data pre and post TAVI + TMVR/r&#xD;
&#xD;
        For phase 2:&#xD;
&#xD;
          -  Patients undergoing successful isolated TAVI&#xD;
&#xD;
          -  Assessment of MR grade prior and post TAVI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Death within 30 days post TAVI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ran Kornowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rabin Medical Center - Hsharon Campus</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Grover FL, Vemulapalli S, Carroll JD, Edwards FH, Mack MJ, Thourani VH, Brindis RG, Shahian DM, Ruiz CE, Jacobs JP, Hanzel G, Bavaria JE, Tuzcu EM, Peterson ED, Fitzgerald S, Kourtis M, Michaels J, Christensen B, Seward WF, Hewitt K, Holmes DR Jr; STS/ACC TVT Registry. 2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol. 2017 Mar 14;69(10):1215-1230. doi: 10.1016/j.jacc.2016.11.033. Epub 2016 Dec 9.</citation>
    <PMID>27956264</PMID>
  </results_reference>
  <results_reference>
    <citation>Nombela-Franco L, Eltchaninoff H, Zahn R, Testa L, Leon MB, Trillo-Nouche R, D'Onofrio A, Smith CR, Webb J, Bleiziffer S, De Chiara B, Gilard M, Tamburino C, Bedogni F, Barbanti M, Salizzoni S, García del Blanco B, Sabaté M, Moreo A, Fernández C, Ribeiro HB, Amat-Santos I, Urena M, Allende R, García E, Macaya C, Dumont E, Pibarot P, Rodés-Cabau J. Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis. Heart. 2015 Sep;101(17):1395-405. doi: 10.1136/heartjnl-2014-307120. Epub 2015 Jun 9. Review. Erratum in: Heart. 2016 May;102(9):728. D Onofrio, Augusto [corrected to D'Onofrio, Augusto].</citation>
    <PMID>26060121</PMID>
  </results_reference>
  <results_reference>
    <citation>Shibayama K, Harada K, Berdejo J, Mihara H, Tanaka J, Gurudevan SV, Siegel R, Jilaihawi H, Makkar RR, Shiota T. Effect of transcatheter aortic valve replacement on the mitral valve apparatus and mitral regurgitation: real-time three-dimensional transesophageal echocardiography study. Circ Cardiovasc Imaging. 2014 Mar;7(2):344-51. doi: 10.1161/CIRCIMAGING.113.000942. Epub 2014 Jan 28.</citation>
    <PMID>24474596</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsang W, Meineri M, Hahn RT, Veronesi F, Shah AP, Osten M, Nathan S, Russo M, Lang RM, Horlick EM. A three-dimensional echocardiographic study on aortic-mitral coupling in transcatheter aortic valve replacement. Eur Heart J Cardiovasc Imaging. 2013 Oct;14(10):950-6. doi: 10.1093/ehjci/jet058. Epub 2013 May 29.</citation>
    <PMID>23720379</PMID>
  </results_reference>
  <results_reference>
    <citation>Harling L, Saso S, Jarral OA, Kourliouros A, Kidher E, Athanasiou T. Aortic valve replacement for aortic stenosis in patients with concomitant mitral regurgitation: should the mitral valve be dealt with? Eur J Cardiothorac Surg. 2011 Nov;40(5):1087-96. doi: 10.1016/j.ejcts.2011.03.036. Epub 2011 May 14.</citation>
    <PMID>21570860</PMID>
  </results_reference>
  <results_reference>
    <citation>Nombela-Franco L, Ribeiro HB, Urena M, Allende R, Amat-Santos I, DeLarochellière R, Dumont E, Doyle D, DeLarochellière H, Laflamme J, Laflamme L, García E, Macaya C, Jiménez-Quevedo P, Côté M, Bergeron S, Beaudoin J, Pibarot P, Rodés-Cabau J. Significant mitral regurgitation left untreated at the time of aortic valve replacement: a comprehensive review of a frequent entity in the transcatheter aortic valve replacement era. J Am Coll Cardiol. 2014 Jun 24;63(24):2643-58. doi: 10.1016/j.jacc.2014.02.573. Epub 2014 Mar 26. Review.</citation>
    <PMID>24681140</PMID>
  </results_reference>
  <results_reference>
    <citation>Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003 Jul;24(13):1231-43.</citation>
    <PMID>12831818</PMID>
  </results_reference>
  <results_reference>
    <citation>Bedogni F, Latib A, De Marco F, Agnifili M, Oreglia J, Pizzocri S, Latini RA, Lanotte S, Petronio AS, De Carlo M, Ettori F, Fiorina C, Poli A, Cirri S, De Servi S, Ramondo A, Tarantini G, Marzocchi A, Fiorilli R, Klugmann S, Ussia GP, Tamburino C, Maisano F, Brambilla N, Colombo A, Testa L. Response to letter regarding article, &quot;Clinical impact of persistent left bundle-branch block after transcatheter aortic valve implantation with CoreValve revalving system&quot;. Circulation. 2013 Nov 26;128(22):e444. doi: 10.1161/CIRCULATIONAHA.113.005705. Erratum in: Circulation. 2014 Feb 4;129(5):e327.</citation>
    <PMID>24276881</PMID>
  </results_reference>
  <results_reference>
    <citation>Cortés C, Amat-Santos IJ, Nombela-Franco L, Muñoz-Garcia AJ, Gutiérrez-Ibanes E, De La Torre Hernandez JM, Córdoba-Soriano JG, Jimenez-Quevedo P, Hernández-García JM, Gonzalez-Mansilla A, Ruano J, Jimenez-Mazuecos J, Castrodeza J, Tobar J, Islas F, Revilla A, Puri R, Puerto A, Gómez I, Rodés-Cabau J, San Román JA. Mitral Regurgitation After Transcatheter Aortic Valve Replacement: Prognosis, Imaging Predictors, and Potential Management. JACC Cardiovasc Interv. 2016 Aug 8;9(15):1603-14. doi: 10.1016/j.jcin.2016.05.025.</citation>
    <PMID>27491611</PMID>
  </results_reference>
  <results_reference>
    <citation>Chakravarty T, Van Belle E, Jilaihawi H, Noheria A, Testa L, Bedogni F, Rück A, Barbanti M, Toggweiler S, Thomas M, Khawaja MZ, Hutter A, Abramowitz Y, Siegel RJ, Cheng W, Webb J, Leon MB, Makkar RR. Meta-analysis of the impact of mitral regurgitation on outcomes after transcatheter aortic valve implantation. Am J Cardiol. 2015 Apr 1;115(7):942-9. doi: 10.1016/j.amjcard.2015.01.022. Epub 2015 Jan 15. Review.</citation>
    <PMID>25779617</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Guy Witberg</investigator_full_name>
    <investigator_title>Consultant cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

